This work is licensed under the Creative Commons Attribution 4.0 International License.
Ezgu F. Inborn errors of metabolism. Adv Clin Chem. 2016;73:195–250. doi: 10.1016/bs.acc.2015.12.001EzguFInborn errors of metabolism20167319525010.1016/bs.acc.2015.12.00126975974Open DOISearch in Google Scholar
Mak CM, Lee HC, Chan AY, Lam CW. Inborn errors of metabolism and expanded newborn screening: review and update. Crit Rev Clin Lab Sci. 2013;50(6):142–62. doi: 10.3109/10408363.2013.847896MakCMLeeHCChanAYLamCWInborn errors of metabolism and expanded newborn screening: review and update20135061426210.3109/10408363.2013.84789624295058Open DOISearch in Google Scholar
Fukao T, Nakamura K. Advances in inborn errors of metabolism. J Hum Genet. 2019;64(2):65. doi: 10.1038/s10038-018-0535-7FukaoTNakamuraKAdvances in inborn errors of metabolism20196426510.1038/s10038-018-0535-730679804Open DOISearch in Google Scholar
Baruteau J, Waddington SN, Alexander IE, Gissen P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J Inherit Metab Dis. 2017;40(4):497–517. doi: 10.1007/s10545-017-0053-3BaruteauJWaddingtonSNAlexanderIEGissenPGene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects201740449751710.1007/s10545-017-0053-3550067328567541Open DOISearch in Google Scholar
Boudes PF. Gene therapy as a new treatment option for inherited monogenic diseases. Eur J Intern Med. 2014;25(1):31–6. doi: 10.1016/j.ejim.2013.09.009BoudesPFGene therapy as a new treatment option for inherited monogenic diseases201425131610.1016/j.ejim.2013.09.00924129166Open DOISearch in Google Scholar
Vink CA, Counsell JR, Perocheau DP, Karda R, Buckley SMK, Brugman MH, et al. Eliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy. Mol Ther. 2017;25(8):1790–804. doi: 10.1016/j.ymthe.2017.04.028VinkCACounsellJRPerocheauDPKardaRBuckleySMKBrugmanMHet alEliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy2017258179080410.1016/j.ymthe.2017.04.028554276628550974Open DOISearch in Google Scholar
Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58. doi: 10.1016/j. ymgme.2003.08.016RaperSEChirmuleNLeeFSWivelNABaggAGaoGPet alFatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer2003801–21485810.1016/j.ymgme.2003.08.01614567964Open DOISearch in Google Scholar
Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013;525(2):174–81. doi: 10.1016/j. gene.2013.03.098MukherjeeSThrasherAJGene therapy for PIDs: progress, pitfalls and prospects201352521748110.1016/j.gene.2013.03.098372541723566838Open DOISearch in Google Scholar
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–8. doi: 10.1056/NEJMoa0802315MaguireAMSimonelliFPierceEAPughEN JrMingozziFBennicelliJet alSafety and efficacy of gene transfer for Leber’s congenital amaurosis2008358212240810.1056/NEJMoa0802315282974818441370Open DOISearch in Google Scholar
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818–23. doi: 10.1126/science.1171242CartierNHacein-Bey-AbinaSBartholomaeCCVeresGSchmidtMKutscheraIet alHematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy200932659548182310.1126/science.117124219892975Open DOISearch in Google Scholar
Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. doi: 10.1126/science.1233158BiffiAMontiniELorioliLCesaniMFumagalliFPlatiTet alLentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy20133416148123315810.1126/science.123315823845948Open DOISearch in Google Scholar
Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876–85. doi: 10.1038/mt.2010.274.NathwaniACRosalesCMcIntoshJRastegarlariGNathwaniDRajDet alLong-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins20111958768510.1038/mt.2010.274309862921245849Open DOISearch in Google Scholar
Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013;24(2):55–64. doi: 10.1089/humc.2013.087BryantLMChristopherDMGilesARHindererCRodriguezJLSmithJBet alLessons learned from the clinical development and market authorization of Glybera2013242556410.1089/humc.2013.087399297723808604Open DOISearch in Google Scholar
Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–288. doi: 10.1146/annurev-med-012017-043332AnguelaXMHighKAEntering the modern era of gene therapy20197027328810.1146/annurev-med-012017-04333230477394Open DOISearch in Google Scholar
Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther. 2006;13(5):839–49. doi: 10.1016/j. ymthe.2006.01.006SandsMSDavidsonBLGene therapy for lysosomal storage diseases20061358394910.1016/j.ymthe.2006.01.00616545619Open DOISearch in Google Scholar
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. G.o.b.m.v. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2. 2011 July 21. London, UK: European Medicines Agency; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdfG.o.b.m.v. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 22011July 21London, UKEuropean Medicines Agency2015Available fromhttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdfSearch in Google Scholar
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341–55. doi: 10.1038/nrg2988. Erratum in: Nat Rev Genet. 2011;12(7):515.MingozziFHighKATherapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges20111253415510.1038/nrg2988Erratum in: Nat Rev Genet. 2011;12(7):51521499295Open DOISearch in Google Scholar
Fraldi A, Serafini M, Sorrentino NC, Gentner B, Aiuti A, Bernardo ME. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr. 2018;44(Suppl 2):130. doi: 10.1186/s13052-018-0565-yFraldiASerafiniMSorrentinoNCGentnerBAiutiABernardoMEGene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches201844Suppl 213010.1186/s13052-018-0565-y623825030442177Open DOISearch in Google Scholar
Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–31. doi: 10.1038/nm.3793CoxDBPlattRJZhangFTherapeutic genome editing: prospects and challenges20152121213110.1038/nm.3793449268325654603Open DOISearch in Google Scholar
Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. 2002;161(3):1169–1175.BibikovaMGolicMGolicKGCarrollDTargeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases200216131169117510.1093/genetics/161.3.1169146216612136019Search in Google Scholar
Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34(3):334–8. doi: 10.1038/nbt.3469YangYWangLBellPMcMenaminDHeZWhiteJet alA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice2016343334810.1038/nbt.3469478648926829317Open DOISearch in Google Scholar
Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med. 2018;24(10):1519–25. doi: 10.1038/s41591-018-0209-1VilligerLGrisch-ChanHMLindsayHRingnaldaFPoglianoCBAllegriGet alTreatment of a metabolic liver disease by in vivo genome base editing in adult mice2018241015192510.1038/s41591-018-0209-130297904Open DOISearch in Google Scholar
Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, et al. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat Commun. 2018;9(1):5454. doi: 10.1038/s41467-018-07827-1ZabaletaNBarberiaMMartin-HiguerasCZapata-LinaresNBetancorIRodriguezSet alCRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I201891545410.1038/s41467-018-07827-1630332330575740Open DOISearch in Google Scholar
Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249–54. doi: 10.1038/s41591-018-0326-xCharlesworthCTDeshpandePSDeverDPCamarenaJLemgartVTCromerMKet alIdentification of preexisting adaptive immunity to Cas9 proteins in humans20192522495410.1038/s41591-018-0326-x719958930692695Open DOISearch in Google Scholar
Perocheau DP, Cunningham S, Lee J, Antinao Diaz J, Waddington SN, Gilmour K, et al. Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort. Hum Gene Ther. 2019;30(1):79–87. doi: 10.1089/hum.2018.098PerocheauDPCunninghamSLeeJAntinaoDiaz JWaddingtonSNGilmourKet alAge-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort2019301798710.1089/hum.2018.098634318430027761Open DOISearch in Google Scholar
Savić N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15–21. doi: 10.1016/j. trsl.2015.09.008SavićNSchwankGAdvances in therapeutic CRISPR/Cas9 genome editing2016168152110.1016/j.trsl.2015.09.00826470680Open DOISearch in Google Scholar
Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther. 2009;11(5):493–503.SackBKHerzogRWEvading the immune response upon in vivo gene therapy with viral vectors2009115493503Search in Google Scholar
Baruteau J, Waddington SN, Alexander IE, Gissen P. Delivering efficient liver-directed AAV-mediated gene therapy. Gene Ther. 2017;24(5):263–4. doi: 10.1038/gt.2016.90BaruteauJWaddingtonSNAlexanderIEGissenP.Delivering efficient liver-directed AAV-mediated gene therapy2017245263410.1038/gt.2016.9028079048Open DOISearch in Google Scholar
Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Version 2. J Clin Invest. 2008;118(9):3132–42. doi: 10.1172/JCI35700Hacein-Bey-AbinaSGarrigueAWangGPSoulierJLimAMorillonEet alInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X12008118931324210.1172/JCI35700249696318688285Open DOISearch in Google Scholar
De Palma M, Montini E, Santoni de Sio FR, Benedicenti F, Gentile A, Medico E, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 2005;105(6):2307–15. doi: 10.1182/blood-2004-03-0798De PalmaMMontiniESantonide Sio FRBenedicentiFGentileAMedicoEet alPromoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells2005105623071510.1182/blood-2004-03-079815542582Open DOISearch in Google Scholar
Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964–75. doi: 10.1172/JCI37630MontiniECesanaDSchmidtMSanvitoFBartholomaeCCRanzaniMet alThe genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy200911949647510.1172/JCI37630266256419307726Open DOISearch in Google Scholar
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873–80. doi: 10.1128/JVI.72.12.9873-9880.1998ZuffereyRDullTMandelRJBukovskyAQuirozDNaldiniLet alSelf-inactivating lentivirus vector for safe and efficient in vivo gene delivery1998721298738010.1128/JVI.72.12.9873-9880.19981104999811723Open DOISearch in Google Scholar
Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest. 2012;122(5):1653–66. doi: 10.1172/JCI61852MoianiAPaleariYSartoriDMezzadraRMiccioACattoglioCet alLentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts2012122516536610.1172/JCI61852Open DOISearch in Google Scholar
Dolgin E. ‘Bubble boy’ gene therapy reignites commercial interest. Nat Biotechnol. 2019;37(7):699–701. doi: 10.1038/d41587-019-00015-6DolginE.‘Bubble boy’ gene therapy reignites commercial interest201937769970110.1038/d41587-019-00015-6Open DOISearch in Google Scholar
Counsell JR, Karda R, Diaz JA, Carey L, Wiktorowicz T, Buckley SMK, et al. Foamy virus vectors transduce visceral organs and hippocampal structures following in vivo delivery to neonatal mice. Mol Ther Nucleic Acids. 2018;12:626–34. doi: 10.1016/j. omtn.2018.07.006CounsellJRKardaRDiazJACareyLWiktorowiczTBuckleySMKet alFoamy virus vectors transduce visceral organs and hippocampal structures following in vivo delivery to neonatal mice2018126263410.1016/j.omtn.2018.07.006Open DOISearch in Google Scholar
Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, et al. Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep. 2017;7:44775. doi: 10.1038/srep44775. Erratum in: Sci Rep. 2017 Aug 29;7:46880.CounsellJRAsgarianZMengJFerrerVVinkCAHoweSJet alLentiviral vectors can be used for full-length dystrophin gene therapy201774477510.1038/srep44775Erratum in: Sci Rep. 2017 Aug 29;7:46880Open DOISearch in Google Scholar
Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1(1):427–51. doi: 10.1146/annurev-virology-031413-085355SamulskiRJMuzyczkaNAAV-mediated gene therapy for research and therapeutic purposes2014114275110.1146/annurev-virology-031413-085355Open DOISearch in Google Scholar
Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): Where are we, and how did we get here? Annu Rev Virol. 2019;6(1):601–21. doi: 10.1146/annurev-virology-092818-015530KeelerAMFlotteTRRecombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): Where are we, and how did we get here?2019616012110.1146/annurev-virology-092818-015530Open DOISearch in Google Scholar
Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–12. doi: 10.1089/hum.2009.182BoutinSMonteilhetVVeronPLeborgneCBenvenisteOMontusMFet al68and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–12. doi10.1089/hum.2009.182Open DOISearch in Google Scholar
Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28(4):308–13. doi: 10.1089/hum.2017.048BernsKIMuzyczkaNAAV: an overview of unanswered questions20172843081310.1089/hum.2017.048Open DOISearch in Google Scholar
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–99. doi: 10.2147/IJN.S68861BozzutoGMolinariA.Liposomes as nanomedical devices2015109759910.2147/IJN.S68861Open DOISearch in Google Scholar
Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface – active agents as observed in the electron miscroscope. J Mol Biol. 1964;8:660–8. doi: 10.1016/s0022-2836(64)80115-7BanghamADHorneRWNegative staining of phospholipids and their structural modification by surface – active agents as observed in the electron miscroscope19648660810.1016/s0022-2836(64)80115-7Open DOISearch in Google Scholar
Mărgineanu DG. Equilibrium and non-equilibrium approaches in biomembrane thermodynamics. Arch Int Physiol Biochim. 1987;95(5):381–422. doi: 10.3109/13813458709075033MărgineanuDGEquilibrium and non-equilibrium approaches in biomembrane thermodynamics198795538142210.3109/138134587090750332452614Open DOISearch in Google Scholar
Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):381–91. doi: 10.3109/21691401.2014.953633DaraeeHEtemadiAKouhiMAlimirzaluSAkbarzadehAApplication of liposomes in medicine and drug delivery20164413819110.3109/21691401.2014.95363325222036Open DOISearch in Google Scholar
Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv. 2011;2011:326497. doi: 10.1155/2011/326497BalazsDAGodbeyWLiposomes for use in gene delivery2011201132649710.1155/2011/326497306657121490748Open DOISearch in Google Scholar
Srinivas R, Samanta S, Chaudhuri A. Cationic amphiphiles: promising carriers of genetic materials in gene therapy. Chem Soc Rev. 2009;38(12):3326–38. doi: 10.1039/b813869aSrinivasRSamantaSChaudhuriACationic amphiphiles: promising carriers of genetic materials in gene therapy2009381233263810.1039/b813869a20449052Open DOISearch in Google Scholar
Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. doi: 10.5772/58459. In: Sezer AD, editor. Application of nanotechnology in drug delivery. London, UK: IntechOpen Limited; 2014 July 25th. doi: 10.5772/57028. ISBN 978-953-51-1628-8. eBook ISBN 978-953-51-5756-4. Available from: https://www.intechopen.com/books/application-of-nanotechnology-in-drug-delivery/liposomes-as-potential-drug-carrier-systems-for-drug-deliveryÇağdaşMSezerADBucakS10.5772/58459SezerADeditor. Application of nanotechnology in drug deliveryLondon, UKIntechOpen Limited2014 July 25th. doi: 10.5772/57028. ISBN 978-953-51-1628-8. eBook ISBN 978-953-51-5756-4. Available fromhttps://www.intechopen.com/books/application-of-nanotechnology-in-drug-delivery/liposomes-as-potential-drug-carrier-systems-for-drug-deliveryOpen DOISearch in Google Scholar
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Ther. 2017;24(8):441–52. doi: 10.1038/gt.2017.41ZylberbergCGaskillKPasleySMatosevicSEngineering liposomal nanoparticles for targeted gene therapy20172484415210.1038/gt.2017.4128504657Open DOISearch in Google Scholar
Zang X, Ding H, Zhao X, Li X, Du Z, Hu H, et al. Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA. Int J Nanomedicine. 2016;11:3951–67. doi: 10.2147/IJN.S107952ZangXDingHZhaoXLiXDuZHuHet alAnti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA20161139516710.2147/IJN.S107952499327927574425Open DOISearch in Google Scholar
Liu YJ, Dou XQ, Wang F, Zhang J, Wang XL, Xu GL, et al. IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment. J Drug Target. 2017;25(3):275–83. doi: 10.1080/1061186X.2016.1258569LiuYJDouXQWangFZhangJWangXLXuGLet alIL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment20172532758310.1080/1061186X.2016.125856927819142Open DOISearch in Google Scholar
Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Controlled Release. 2013;167(1):1–10. doi: 10.1016/j.jconrel.2013.01.016SharmaGModgilALayekBAroraKSunCLawBet alCell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection2013167111010.1016/j.jconrel.2013.01.01623352910Open DOISearch in Google Scholar
Saffari M, Moghimi HR, Dass CR. Barriers to liposomal gene delivery: from application site to the target. Iran J Pharm Res. 2016 Winter;15(Suppl):3–17.SaffariMMoghimiHRDassCRBarriers to liposomal gene delivery: from application site to the target201615Suppl317Search in Google Scholar
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi: 10.1186/1556-276X-8-102AkbarzadehARezaei-SadabadyRDavaranSJooSWZarghamiNHanifehpourYet alLiposome: classification, preparation, and applications20138110210.1186/1556-276X-8-102359957323432972Open DOISearch in Google Scholar
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–16. doi: 10.1016/j.addr.2013.12.008OzpolatBSoodAKLopez-BeresteinGLiposomal siRNA nanocarriers for cancer therapy2014661101610.1016/j.addr.2013.12.008452716524384374Open DOISearch in Google Scholar
Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910–8. doi: 10.1158/0008-5472.CAN-05-0530LandenCN JrChavez-ReyesABucanaCSchmandtRDeaversMTLopez-BeresteinGet alTherapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery200565156910810.1158/0008-5472.CAN-05-053016061675Open DOISearch in Google Scholar
Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, Pereira de Almeida L. Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. J Control Release. 2017;262:247-258. doi: 10.1016/j.jconrel.2017.07.001.Rufino-RamosDAlbuquerquePRCarmonaVPerfeitoRNobreRJPereira de AlmeidaLExtracellular vesicles: Novel promising delivery systems for therapy of brain diseases201726224725810.1016/j.jconrel.2017.07.00128687495Open DOISearch in Google Scholar
Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75(2):193–208. doi: 10.1007/s00018-017-2595-9HessvikNPLlorenteA.Current knowledge on exosome biogenesis and release201875219320810.1007/s00018-017-2595-9575626028733901Open DOISearch in Google Scholar
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi: 10.1038/ncb1596ValadiHEkströmKBossiosASjöstrandMLeeJJLötvallJOExosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells20079665465910.1038/ncb159617486113Open DOISearch in Google Scholar
Bang C, Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol. 2012;44(11):2060–4. doi: 10.1016/j.biocel.2012.08.007BangCThumTExosomes: new players in cell-cell communication201244112060410.1016/j.biocel.2012.08.00722903023Open DOISearch in Google Scholar
De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203. doi: 10.3389/fimmu.2015.00203De ToroJHerschlikLWaldnerCMonginiCEmerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications2015620310.3389/fimmu.2015.00203441817225999947Open DOISearch in Google Scholar
Arenaccio C, Federico M. The multifaceted functions of exosomes in health and disease: an overview. Adv Exp Med Biol. 2017;998:3–19. doi: 10.1007/978-981-10-4397-0_1ArenaccioCFedericoMThe multifaceted functions of exosomes in health and disease: an overview201799831910.1007/978-981-10-4397-0_128936729Open DOISearch in Google Scholar
Jiang XC, Gao JQ. Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm. 2017;521(1–2):167–75. doi: 10.1016/j. ijpharm.2017.02.038JiangXCGaoJQExosomes as novel bio-carriers for gene and drug delivery20175211–21677510.1016/j.ijpharm.2017.02.03828216464Open DOISearch in Google Scholar
Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21(1):185–91. doi: 10.1038/mt.2012.180OhnoSTakanashiMSudoKUedaSIshikawaAMatsuyamaNet alSystemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells20132111859110.1038/mt.2012.180353830423032975Open DOISearch in Google Scholar
Wahlgren J, De L Karlson T, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012;40(17):e130. doi: 10.1093/nar/gks463WahlgrenJDe LKarlson TBrisslertMVaziriSani FTelemoESunnerhagenPet alPlasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes20124017e13010.1093/nar/gks463345852922618874Open DOISearch in Google Scholar
Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol. 2014;306(7):C621–33. doi: 10.1152/ajpcell.00228.2013TurturiciGTinnirelloRSconzoGGeraciFExtracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages20143067C6213310.1152/ajpcell.00228.201324452373Open DOISearch in Google Scholar
Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Controlled Release. 2015;207:18–30. doi: 10.1016/j. jconrel.2015.03.033HaneyMJKlyachkoNLZhaoYGuptaRPlotnikovaEGHeZet alExosomes as drug delivery vehicles for Parkinson’s disease therapy2015207183010.1016/j.jconrel.2015.03.033443038125836593Open DOISearch in Google Scholar
Mentkowski KI, Lang JK. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo. Sci Rep. 2019;9(1):10041. doi: 10.1038/s41598-019-46407-1MentkowskiKILangJKExosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo2019911004110.1038/s41598-019-46407-1662424831296886Open DOISearch in Google Scholar
Bunggulawa EJ, Wang W, Yin T, Wang N, Durkan C, Wang Y, et al. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnol. 2018;16(1):81. doi: 10.1186/s12951-018-0403-9BunggulawaEJWangWYinTWangNDurkanCWangYet alRecent advancements in the use of exosomes as drug delivery systems20181618110.1186/s12951-018-0403-9619056230326899Open DOISearch in Google Scholar
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287–96. doi: 10.1016/j.apsb.2016.02.001HaDYangNNaditheVExosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges2016642879610.1016/j.apsb.2016.02.001495158227471669Open DOISearch in Google Scholar
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17. doi: 10.1038/s41556-018-0250-9MathieuMMartin-JaularLLavieuGThéryCSpecificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication201921191710.1038/s41556-018-0250-930602770Open DOISearch in Google Scholar
Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther. 1999;10(15):2515–26. doi: 10.1089/10430349950016852NunesFAFurthEEWilsonJMRaperSEGene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration1999101525152610.1089/1043034995001685210543616Open DOISearch in Google Scholar
Do MA, Levy D, Brown A, Marriott G, Lu B. Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles. Sci Rep. 2019;9(1):17274. doi: 10.1038/s41598-019-53844-5DoMALevyDBrownAMarriottGLuBTargeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles2019911727410.1038/s41598-019-53844-5687276731754156Open DOISearch in Google Scholar
Yim N, Ryu SW, Choi K, Lee KR, Lee S, Choi H, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun. 2016;7:12277. doi: 10.1038/ncomms12277YimNRyuSWChoiKLeeKRLeeSChoiHet alExosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module201671227710.1038/ncomms12277496186527447450Open DOISearch in Google Scholar
Del Pozo-Rodríguez A, Solinís MÁ, Rodríguez-Gascón A. Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 2016;109:184–93. doi: 10.1016/j.ejpb.2016.10.016Del Pozo-RodríguezASolinísMÁRodríguez-GascónAApplications of lipid nanoparticles in gene therapy20161091849310.1016/j.ejpb.2016.10.01627789356Open DOISearch in Google Scholar
Blakney AK, McKay PF, Yus BI, Aldon Y, Shattock RJ. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26(9):363–72. doi: 10.1038/s41434-019-0095-2BlakneyAKMcKayPFYusBIAldonYShattockRJInside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA20192693637210.1038/s41434-019-0095-2676053531300730Open DOISearch in Google Scholar
Berraondo P, Martini PGV, Avila MA, Fontanellas A. Messenger RNA therapy for rare genetic metabolic diseases. Gut. 2019;68(7):1323–30. doi: 10.1136/gutjnl-2019-318269BerraondoPMartiniPGVAvilaMAFontanellasAMessenger RNA therapy for rare genetic metabolic diseases201968713233010.1136/gutjnl-2019-31826930796097Open DOISearch in Google Scholar
Martini PGV, Guey LT. A new era for rare genetic diseases: messenger RNA therapy. Hum Gene Ther. 2019;30(10):1180–9. doi: 10.1089/hum.2019.090MartiniPGVGueyLTA new era for rare genetic diseases: messenger RNA therapy201930101180910.1089/hum.2019.09031179759Open DOISearch in Google Scholar
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–58. doi: 10.4103/0250-474X.57282MukherjeeSRaySThakurRSSolid lipid nanoparticles: a modern formulation approach in drug delivery system20097143495810.4103/0250-474X.57282286580520502539Open DOISearch in Google Scholar
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109(36):14604–9. doi: 10.1073/pnas.1209367109GeallAJVermaAOttenGRShawCAHekeleABanerjeeKet alNonviral delivery of self-amplifying RNA vaccines20121093614604910.1073/pnas.1209367109343786322908294Open DOISearch in Google Scholar
Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–94. doi: 10.1002/iub.230PeggAE.Mammalian polyamine metabolism function20096198809410.1002/iub.230275342119603518Open DOISearch in Google Scholar
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357–64. doi: 10.1038/mt.2010.85AkincAQuerbesWDeSQinJFrank-KamenetskyMJayaprakashKNet alTargeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms201018713576410.1038/mt.2010.85291126420461061Open DOISearch in Google Scholar
An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–58. doi: 10.1016/j.celrep.2017.11.081. Erratum in: Cell Rep. 2018;24(9):2520.AnDSchnellerJLFrassettoALiangSZhuXParkJSet alSystemic messenger RNA therapy as a treatment for methylmalonic acidemia2017211235485810.1016/j.celrep.2017.11.081Erratum in: Cell Rep. 2018;24(9):252029262333Open DOISearch in Google Scholar
Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899-909. doi: 10.1038/s41591-018-0199-zJiangLBerraondoPJericóDGueyLTSampedroAFrassettoAet alSystemic messenger RNA as an etiological treatment for acute intermittent porphyria20182412189990910.1038/s41591-018-0199-z30297912Open DOISearch in Google Scholar
Inagaki K, Piao C, Kotchey NM, Wu X, Nakai H. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. J Virol. 2008;82(19):9513–24. doi: 10.1128/JVI.01001-08InagakiKPiaoCKotcheyNMWuXNakaiHFrequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver2008821995132410.1128/JVI.01001-08254694918614641Open DOISearch in Google Scholar
Prieve MG, Harvie P, Monahan SD, Roy D, Li AG, Blevins TL, et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Mol Ther. 2018;26(3):801–13. doi: 10.1016/j.ymthe.2017.12.024PrieveMGHarviePMonahanSDRoyDLiAGBlevinsTLet alTargeted mRNA therapy for ornithine transcarbamylase deficiency20182638011310.1016/j.ymthe.2017.12.024591066929433939Open DOISearch in Google Scholar
Truong B, Allegri G, Liu XB, Burke KE, Zhu X, Cederbaum SD, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci USA. 2019;116(42):21150–9. doi: 10.1073/pnas.1906182116TruongBAllegriGLiuXBBurkeKEZhuXCederbaumSDet alLipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency20191164221150910.1073/pnas.1906182116680036031501335Open DOISearch in Google Scholar
Balakrishnan B, An D, Nguyen V, DeAntonis C, Martini PGV, Lai K. Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia. Mol Ther. 2020;28(1):304–12. doi: 10.1016/j.ymthe.2019.09.018BalakrishnanBAnDNguyenVDeAntonisCMartiniPGVLaiKNovel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia20202813041210.1016/j.ymthe.2019.09.018695216531604675Open DOISearch in Google Scholar
Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Sci Transl Med. 2017;9(418):eaam6375. doi: 10.1126/scitranslmed.aam6375PuzzoFColellaPBiferiMGBaliDPaulkNKVidalPet alRescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase2017941810.1126/scitranslmed.aam6375582661129187643Open DOISearch in Google Scholar
Baruteau J, Waddington SN. Fetal gene therapy for neurodegenerative lysosomal storage diseases. J Inherit Metab Dis. 2019;42(3):391–3. doi: 10.1002/jimd.12018BaruteauJWaddingtonSNFetal gene therapy for neurodegenerative lysosomal storage diseases2019423391310.1002/jimd.1201830715735Open DOISearch in Google Scholar
Hocquemiller M, Hemsley KM, Douglass ML, Tamang SJ, Neumann D, King BM, et al. AAVrh10 vector corrects disease pathology in MPS IIIA mice and achieves widespread distribution of SGSH in large animal brains. Mol Ther Methods Clin Dev. 2019;17:174–87. doi: 10.1016/j.omtm.2019.12.001HocquemillerMHemsleyKMDouglassMLTamangSJNeumannDKingBMet alAAVrh10 vector corrects disease pathology in MPS IIIA mice and achieves widespread distribution of SGSH in large animal brains2019171748710.1016/j.omtm.2019.12.001694061531909089Open DOISearch in Google Scholar
Ellison SM, Liao A, Wood S, Taylor J, Youshani AS, Rowlston S, et al. Pre-clinical safety and efficacy of lentiviral vector-mediated ex vivo stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA. Mol Ther Methods Clin Dev. 2019;13:399–413. doi: 10.1016/j.omtm.2019.04.001EllisonSMLiaoAWoodSTaylorJYoushaniASRowlstonSet alPre-clinical safety and efficacy of lentiviral vector-mediated ex vivo stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA20191339941310.1016/j.omtm.2019.04.001647920431044143Open DOISearch in Google Scholar
Torres-Torronteras J, Cabrera-Pérez R, Vila-Julià F, Viscomi C, Cámara Y, Hirano M, et al. Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2018;29(6):708–18. doi: 10.1089/hum.2017.133Torres-TorronterasJCabrera-PérezRVila-JuliàFViscomiCCámaraYHiranoMet alLong-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy20182967081810.1089/hum.2017.133764793129284302Open DOISearch in Google Scholar
Cunningham SC, Kok CY, Spinoulas A, Carpenter KH, Alexander IE. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia. Gene Ther. 2013;20(12):1184–7. doi: 10.1038/gt.2013.51CunninghamSCKokCYSpinoulasACarpenterKHAlexanderIEAAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia201320121184710.1038/gt.2013.5124108150Open DOISearch in Google Scholar
Kok CY, Cunningham SC, Carpenter KH, Dane AP, Siew SM, Logan GJ, et al. Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice. Mol Ther. 2013;21(10):1823–31. doi: 10.1038/mt.2013.139KokCYCunninghamSCCarpenterKHDaneAPSiewSMLoganGJet alAdeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice2013211018233110.1038/mt.2013.139380813623817206Open DOISearch in Google Scholar
Baruteau J, Perocheau DP, Hanley J, Lorvellec M, Rocha-Ferreira E, Karda R, et al. Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nat Commun. 2018;9(1):3505. doi: 10.1038/s41467-018-05972-1BaruteauJPerocheauDPHanleyJLorvellecMRocha-FerreiraEKardaRet alArgininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer201891350510.1038/s41467-018-05972-1611541730158522Open DOISearch in Google Scholar
Hu C, Tai DS, Park H, Cantero G, Cantero-Nieto G, Chan E, et al. Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy. Gene Ther. 2015;22(2):111–5. doi: 10.1038/gt.2014.106HuCTaiDSParkHCanteroGCantero-NietoGChanEet alMinimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy2015222111510.1038/gt.2014.106432001525474440Open DOISearch in Google Scholar
Ou L, DeKelver RC, Rohde M, Tom S, Radeke R, St Martin SJ, et al. ZFN-mediated in vivo genome editing corrects murine hurler syndrome. Mol Ther. 2019;27(1):178–87. doi: 10.1016/j. ymthe.2018.10.018OuLDeKelverRCRohdeMTomSRadekeRStMartin SJet alZFN-mediated in vivo genome editing corrects murine hurler syndrome20192711788710.1016/j.ymthe.2018.10.018631931530528089Open DOISearch in Google Scholar
Laoharawee K, DeKelver RC, Podetz-Pedersen KM, Rohde M, Sproul S, Nguyen HO, et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther. 2018;26(4):1127– 36. doi: 10.1016/j.ymthe.2018.03.002LaoharaweeKDeKelverRCPodetz-PedersenKMRohdeMSproulSNguyenHOet alDose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing20182641127–3610.1016/j.ymthe.2018.03.002608013129580682Open DOISearch in Google Scholar
Cunningham SC, Siew SM, Hallwirth CV, Bolitho C, Sasaki N, Garg G, et al. Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system. Hepatology. 2015;62(2):417–28. doi: 10.1002/hep.27842CunninghamSCSiewSMHallwirthCVBolithoCSasakiNGargGet alModeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system20156224172810.1002/hep.2784226011400Open DOISearch in Google Scholar
Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630–8. doi: 10.1056/NEJMoa1700554EichlerFDuncanCMusolinoPLOrchardPJDe OliveiraSThrasherAJet alHematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy2017377171630810.1056/NEJMoa1700554570884928976817Open DOISearch in Google Scholar
Poletti V, Biffi A. Gene-based approaches to inherited neurometabolic diseases. Hum Gene Ther. 2019;30(10):1222– 35. doi: 10.1089/hum.2019.190PolettiVBiffiAGene-based approaches to inherited neurometabolic diseases201930101222–3510.1089/hum.2019.19031397176Open DOISearch in Google Scholar
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964–79. doi: 10.1016/j.healthpol.2014.12.016AngelisATordrupDKanavosPSocio-economic burden of rare diseases: a systematic review of cost of illness evidence201511979647910.1016/j.healthpol.2014.12.01625661982Open DOISearch in Google Scholar
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–27. doi: 10.1056/NEJMoa1708538GeorgeLASullivanSKGiermaszARaskoJEJSamelson-JonesBJDucoreJet alHemophilia B gene therapy with a high-specific-activity factor IX variant20173772322152710.1056/NEJMoa1708538602962629211678Open DOISearch in Google Scholar